Varizig Approved for Reducing Severity of Chickenpox

VARIZIG Lyophilized (varicella zoster immune globulin [human])
VARIZIG Lyophilized (varicella zoster immune globulin [human])

The FDA has approved Varizig (varicella zoster immune globulin [human]; Cangene) for reducing the severity of chicken pox (varicella zoster virus [VZV]) infections in high-risk individuals when given within four days after exposure. High-risk individuals include immunocompromised children and adults, newborns, pregnant women, premature infants, children <1 year old, and adults with no immunity to VZV.

Varizig is an antibody preparation manufactured from plasma of healthy donors with high anti-VZV antibody levels. The donated plasma comes from FDA-licensed collection facilities in the United States and Canada. It is the only FDA-approved immune globulin for varicella zoster virus after exposure. An earlier FDA-licensed varicella zoster immune globulin (VZIG) was removed from the market in 2006.

Clinical studies have shown Varizig to be comparable and effective as VZIG in preventing infection during pregnancy. Further data showed a low rate of severe VZV infection in susceptible individuals compared with the rate in untreated individuals.

For more information call (877) 226-4363 or visit www.cangene.com.